Research Paper Volume 12, Issue 1 pp 481—501

A novel rhamnoside derivative PL402 up-regulates matrix metalloproteinase 3/9 to promote Aβ degradation and alleviates Alzheimer’s-like pathology


Figure 5. PL402 alleviates Aβ burden and promotes Aβ degradation in vivo. (A, B) Representative images (A) of Aβ plaques in APP/PS1 mice immunostained with the Aβ antibody 6E10 in coronal mouse brain cryo-sections (n = 5 per group) and the number of Aβ plaques (B), were quantified from entire brain sections using Image-Pro Plus 5.1 software (Media Cybernetics), scale bar =500 um. (C, D) SDS-soluble and FA (formic acid)-soluble Aβ40 and Aβ42 levels in mouse cortex (Cx) and hippocampus (Hp) measured by ELISA. (E) The expression of Aβ degradation enzymes (MMP3 and MMP9) in vehicle- or PL402-treated APP/PS1 mice detected by western blot analysis. N=6 mice. (F) The quantification of (E) using image J. *p<0.05, **p<0.01, ***p< 0.001 and ***p< 0.0001 compared to the control of each group. One-way ANOVA or two-way ANOVA followed by Bonferroni test.